Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.39 |
| ▸ | FURIN | P09958 | 2/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18244335 | 0.97 | FAP (0.40) | FAPFURINHRH1HTTMAP1LC3B | |
| SCHEMBL18244334 | 0.97 | FAP (0.40) | FAPFURINHRH1HTTMAP1LC3B | |
| SCHEMBL23286101 | 0.93 | FAP (0.42) | FAPFURINROCK2HTTMAP1LC3B | |
| SCHEMBL24848129 | 0.93 | FAP (0.44) | FAPFURINROCK2HTTMAP1LC3B | |
| SCHEMBL24500888 | 0.93 | FAP (0.40) | FAPFURINHRH1MAP1LC3B | |
| SCHEMBL15246622 | 0.92 | FAP (0.44) | FAPFURINROCK2HTTMAP1LC3B | |
| SCHEMBL22336599 | 0.92 | FAP (0.40) | FAPFURINHTTSIRT2SIRT1 | |
| SCHEMBL3244447 | 0.92 | FAP (0.44) | FAPFURINROCK2HTTMAP1LC3B | |
| SCHEMBL21416485 | 0.92 | FAP (0.44) | FAPFURINROCK2HTTMAP1LC3B | |
| SCHEMBL16266184 | 0.92 | FAP (0.44) | FAPFURINROCK2HTTMAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | FAP 4053/4885FURIN 1569/4885HRH1 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.